Schwab Charles Investment Management Inc. grew its stake in shares of Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 153.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 213,261 shares of the company’s stock after purchasing an additional 129,089 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Senseonics were worth $877,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Gilder Gagnon Howe & Co. LLC purchased a new position in Senseonics during the 2nd quarter valued at about $74,936,000. Bank of Montreal Can purchased a new position in Senseonics during the 2nd quarter valued at about $1,030,000. Broadview Advisors LLC purchased a new position in Senseonics during the 2nd quarter valued at about $2,774,000. Emerald Mutual Fund Advisers Trust purchased a new position in Senseonics during the 2nd quarter valued at about $1,531,000. Finally, Rhumbline Advisers purchased a new position in Senseonics during the 2nd quarter valued at about $255,000. 30.66% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSEAMERICAN SENS opened at $3.79 on Wednesday. Senseonics Holdings Inc has a 1 year low of $2.36 and a 1 year high of $5.29. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81.
SENS has been the subject of a number of recent research reports. Raymond James lifted their price target on shares of Senseonics from $4.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, June 22nd. Dougherty & Co initiated coverage on shares of Senseonics in a research report on Friday, August 24th. They set a “buy” rating and a $6.00 price target for the company. Finally, BTIG Research reissued a “buy” rating and set a $6.00 price target on shares of Senseonics in a research report on Thursday, August 9th. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $6.00.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More: What is insider trading?
Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings Inc (NYSEAMERICAN:SENS).
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.